Paratek Pharmaceuticals, Inc.
PRTK · NASDAQ
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Revenue | $38 | $29 | $73 | $28 |
| % Growth | 30.3% | -59.8% | 160.8% | – |
| Cost of Goods Sold | $4 | $6 | $10 | $4 |
| Gross Profit | $34 | $23 | $62 | $23 |
| % Margin | 88.5% | 78.6% | 85.8% | 84.3% |
| R&D Expenses | $9 | $7 | $14 | $8 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $36 | $33 | $54 | $34 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | -$2 | -$3 | -$2 |
| Operating Expenses | $43 | $39 | $65 | $40 |
| Operating Income | -$9 | -$16 | -$3 | -$16 |
| % Margin | -24.7% | -54.1% | -3.9% | -59.2% |
| Other Income/Exp. Net | -$5 | -$4 | -$4 | -$4 |
| Pre-Tax Income | -$15 | -$20 | -$7 | -$21 |
| Tax Expense | $0 | $0 | $0 | $4 |
| Net Income | -$15 | -$20 | -$7 | -$25 |
| % Margin | -38.2% | -69% | -9.9% | -90.7% |
| EPS | -0.25 | -0.35 | -0.13 | -0.46 |
| % Growth | 28.6% | -169.2% | 71.7% | – |
| EPS Diluted | -0.25 | -0.35 | -0.13 | -0.46 |
| Weighted Avg Shares Out | 57 | 57 | 54 | 55 |
| Weighted Avg Shares Out Dil | 57 | 57 | 54 | 55 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $5 | $4 | $5 | $5 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$9 | -$16 | -$2 | -$16 |
| % Margin | -24.1% | -53.3% | -3.4% | -58.2% |